-
Mercati
athexgroup.grAthens Exchange GroupLeggi tuttoTogether for a unified, stronger European capital market.
-
Azioni
Sustainable finance2025 Euronext ESG Trends ReportLeggi tuttoA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indici
Access the white paperInvesting in the future of Europe with innovative indicesLeggi tuttoThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETF
The European market place for ETFsEuronext ETF EuropeLeggi tuttoInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fondi
-
Obbligazioni
European Defence BondsGroupe BPCE lists the first bondLeggi tuttoFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Prodotti strutturati
-
Derivati
Where European Government Bonds Meet the FutureTrade Mini Bond FuturesLeggi tuttoTrade mini bond futures on main European government bonds
-
Commodities
- Panoramica
- Agricultural quotes
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Dairy derivatives
- Salmon derivatives
- Container Freight Futures
- Consegna e liquidazione
- Specifiche e disposizioni
- Commitments of Traders (CoT) report
- Commodity brokers
Take control of unpredictable dairy pricesEuropean Dairy DerivativesLeggi tuttoFutures and options on butter and skimmed milk powder now trading.
-
Documenti e risorse
Designed to help students navigate the complexities of financial marketsEuronext Trading gameLeggi tuttoJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
DNA drug developer Seawolf launches with $100 million funding, Sanofi deal
Nov 16 (Reuters) - Seawolf Therapeutics on Monday launched publicly with $100 million in funding and a deal with French drugmaker Sanofi worth up to $1.2 billion, as it seeks to develop DNA-based medicines.
• The Series A financing was backed by Versant Ventures, MPM BioImpact and Novartis Venture Fund, with participation from Eli Lilly, CRISPR Therapeutics and others
• San Diego-based Seawolf and Sanofi will develop treatments for bleeding disorders and other undisclosed conditions
• Seawolf could get milestone payments and royalties
• CEO Elizabeth Alcamo told Reuters the agreement includes an upfront payment, though she declined to say how much
• Seawolf's technology, called TRIDENT, uses tiny fat particles to carry DNA into the nucleus of cells without using viruses
• The company says it can offer longer-lasting effects than RNA medicines and the option of repeat dosing that virus-based gene therapies lack
• The lead program, which has been tested only in animals, aims to build muscle and reduce fat, and could be used for obesity, muscle loss and osteoporosis
• Seawolf expects to pick a drug candidate by late 2027 and file to begin human trials by the end of 2028
• But "we'll probably need to raise some additional capital" to reach that stage, Alcamo said
(Reporting by Kamal Choudhury in Bengaluru; Editing by Sahal Muhammed)
Find it fast
Looking for more insights? Explore our other news sections for updates on sustainable finance, companies and financial education